GeoVax Labs, Inc. - Common Stock (GOVX)
1.0200
+0.0401 (4.09%)
NASDAQ · Last Trade: May 22nd, 5:58 PM EDT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 21, 2025
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
GeoVax’s Advanced MVA Manufacturing Platform Supports ASPR-DARPA Vision for Scalable, AI-Integrated Pharmaceutical Production
Via TheNewswire.com · May 21, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 20, 2025
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
GEO-CM04S1 Demonstrates Superior Protection in Immunocompromised Populations; Fully Aligned with HHS Priorities for Durable, Broad-Spectrum Immunization
Via TheNewswire.com · May 20, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 8, 2025
GeoVax Expands Gedeptin(R) Patent Portfolio
Allowed Patent Claims Cover the Synergistic Combination of Gedeptin® Therapy with Radiation As a Targeted Approach for Solid Tumors
Via TheNewswire.com · May 7, 2025
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin’s Potential in Solid Tumors
Via TheNewswire.com · April 29, 2025
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities
Via TheNewswire.com · April 22, 2025
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
GEO-CM04S1 Demonstrates Robust COVID-19 and Mpox Immunogenicity in Immunocompromised Patients and Healthy Adults
Via TheNewswire.com · May 8, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 7, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 6, 2025
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Company’s Advanced Manufacturing Proposal Supports National Biosecurity Goals and Executive Action on Domestic Pharmaceutical Supply Chains
Via TheNewswire.com · May 6, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 1, 2025
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025
Via TheNewswire.com · May 1, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 29, 2025
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate
Via TheNewswire.com · April 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 24, 2025
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations
Via TheNewswire.com · April 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 23, 2025
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
GeoVax to Host Conference Call at 4:30 PM ET
Via TheNewswire.com · April 23, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 16, 2025
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
Peer-Reviewed Data Reinforces GeoVax’s Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs
Via TheNewswire.com · April 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · April 16, 2025